Endometrial Cancer

P1, N=94, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

P1/2, N=188, Recruiting, STORM Therapeutics LTD | Trial completion date: Jan 2026 --> Jun 2027 | Trial primary completion date: Oct 2025 --> Dec 2026

P3, N=700, Recruiting, AstraZeneca | N=183 --> 700 | Trial completion date: Apr 2028 --> Jul 2029

The patient therefore underwent adjuvant carboplatin/paclitaxel chemotherapy followed by vaginal brachytherapy and has remained recurrence-free for five years. This case demonstrates molecular classification of an unusual histological type of EC exhibiting an extremely short-term risk of early distant metastasis and its implication on aggressive adjuvant therapeutical approach. It, furthermore, exemplifies the pronounced heterogeneity of the NSMP subgroup.

Furthermore, the present review discussed recent progress in structural modifications aimed at enhancing selectivity while reducing toxicity, as well as novel targeting strategies. Concluding with perspectives on HDAC-based therapies, the present review underscores the key importance of precision targeting and combinatorial approaches to improve patient outcomes in the future.

P=N/A, N=200, Completed, University College Cork | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Mar 2026

P2, N=290, Not yet recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

For stage Ⅲ and above mismatch repair-deficient (MMRd) endometrial cancer, postoperative paclitaxel plus carboplatin chemotherapy combined with ICIs and maintenance therapy are recommended. Many issues remain to be resolved, such as whether MMRd endometrial cancer caused by MLH-1 methylation or mutations in MMR-encoding genes has consistent responses to ICIs, and how to predict treatment efficacy. The reduced cost and rapid popularization of high-throughput technologies, as well as the continuous expansion and improvement of evidence from prospective cohorts, will provide high-quality evidence for further refinement of molecular characteristics and risk stratification of endometrial cancer, and guide the implementation of precision treatment for this disease.

P2, N=131, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

VSELs regenerate damaged and diseased tissues when a healthy paracrine support is provided by the transplanted MUSE cells/MSCs; however, remain elusive due to their small size and scarce nature. In summary, the view that MUSE cells phagocytose damaged cells and subsequently differentiate into the same cell type is fundamentally challenged and requires careful re-evaluation.

However, neither marker demonstrated independent prognostic value for survival outcomes. Further studies are warranted to clarify the role of ER stress pathways in EC biology and their potential implications for risk stratification and targeted therapy.

This in silico immune network highlights checkpoint centered hubs and coordinated immune programs with prognostic relevance in endometrial cancer, providing a rationale for biomarker guided immunotherapy development and patient stratification. Validation in independent cohorts and correlation with clinicopathologic and treatment response data are needed to support clinical translation.